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Abstract 
Aim: To assess comorbidities of patients who suffer a cardiac arrest in the hospital; immediate 
clinical antecedents of arrest and outcomes for all patients and to compare between 
monitored vs. unmonitored and dead vs. alive at discharge. 
Methods: Patients admitted to the hospital in 2009, ≥ 18 years old, with in-hospital cardiac 
arrest >24hours after admission were included. T student test was performed for continuous 
variables; χ2 tests for categorical data and Mann—Whitney U-test for non-normal, continuous 
data.  
Results: A total of 66 patients were included. The survival to discharge was 30.3%. Return of 
spontaneous circulation occurred in 88% of patients. One year survival of those discharged 
alive was around 55-85%. Only 6% did not have pre-existing morbidities. Over 80% of patients 
had clinical anomalies <24h prior to arrest. Forty (60.6%) patients were monitored and 26 
(39.4%) were unmonitored. Most patients with a cardiac illness were monitored at the time of 
the event (p=0.02). Forty-six (69.7%) patients died in-hospital and 20 (30.3%) were discharged 
alive. The mean in-hospital days after cardiac arrest was significantly higher in survivors than in 
non-survivors (p=0.01). Non-survivors received defibrillation more frequently than survivors 
(p= 0.02). 
Conclusion: Most patients that suffer in-hospital cardiac arrest have pre-existing morbidities 
and abnormal observations preceding cardiac arrest. There were no significant differences 
between monitored and unmonitored patients, except for illness category. We could not find 
distinctive characteristics between patients who died in-hospital and those who survived, 
except for a longer in-hospital stay for survivors and more frequent defibrillation in non-
survivors. 
Keywords: in-hospital cardiac arrest, outcome, morbidity, Charlson score, clinical antecedents, 
monitored. 
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Introduction 
The history of modern cardiopulmonary resuscitation (CPR) dates back to the 1960s, 
when methods of closed chest cardiac massage were first described.1 In 1963, the American 
Heart Association formally endorsed CPR, which became an integral part of care in all patients 
facing imminent death.2 In Portugal, the Portuguese Resuscitation Council was established in 
1998.3 
CPR is an attempt to restore spontaneous circulation by performing chest 
compressions with or without ventilations.4  
 Cardiac arrest can be defined as the cessation of cardiac mechanical activity as 
confirmed by the absence of signs of circulation.4 According to the Utstein criteria, a cardiac 
arrest is classified as 'in-hospital' if it occurs in a hospitalised patient who had a pulse at the 
time of admission.5 
In 1977, the survival to discharge after in-hospital cardiac arrest was 8.7%.6 Nowadays, 
survival remains low, typically ranging from 15 to 23%.7 Among those who are successfully 
resuscitated, between 25% and 67% die during the first 24 hours after return of spontaneous 
circulation (ROSC). One year after the arrest, reported survival of the originally discharged 
patients ranges between 53% and 86%.5 
The three most common reasons for in-hospital cardiac arrest in adults are cardiac 
arrhythmia, acute respiratory insufficiency, and hypotension.8 Studies have shown evidence of 
abnormal clinical signs in up to 80% of patients during the hours preceding the cardiac 
arrest.5,7 The observation of deterioration in clinical condition of patients prior to cardiac arrest 
supports the idea that it is neither a sudden nor unpredictable event.9  
Furthermore, three-quarters of adult survivors of CPR have one or more co-existing 
conditions, such as cardiac disease, cancer or diabetes.10 
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  The main goals of this study were to assess: comorbidities of patients who suffer a 
cardiac arrest in the hospital; immediate clinical antecedents of arrest and the outcomes for all 
patients and to compare between monitored vs. unmonitored and dead vs. alive at discharge. 
Methods 
Data collection 
All patients admitted to the hospital in 2009 and which were attributed the code  
“cardiac arrest” were included and their files were reviewed as well as copies of the death 
certificates of patients who died in the hospital, and, whenever available, charts of the medical 
emergency team (MET) were also analyzed. The post-discharge data was obtained through 
consultation of registries of later admissions or appointments at the hospital. The ethics 
committee of the Hospital S. João approved this study. 
 The information was collected according to the Utstein style guidelines, developed for 
reviewing, reporting, and conducting research on in-hospital resuscitation.8  
 In addition, the records were reviewed in order to allow the calculation of the Charlson 
age-comorbidity index, which is the most extensively studied comorbidity index. It 
encompasses 19 medical conditions selected and weighted 1–6 on the basis of the strength of 
their association with mortality, with total scores ranging from 0–37.11-13  
Inclusion criteria: 
All adult (≥18 years of age) patients, who experience a resuscitation event were 
eligible for inclusion. A resuscitation event is defined as an acute respiratory compromise that 
requires emergency assisted ventilation leading to cardiopulmonary arrest that requires chest 
compressions and/or defibrillation, or cardiopulmonary arrest that requires chest 
compressions and/or defibrillation, and elicits an emergency resuscitation response by facility 
personnel, and a resuscitation record is completed for the event.8 
Exclusion criteria: 
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The following events were excluded: individuals who did not fulfil the inclusion criteria 
above and events that occurred less than 24hours after admission in the hospital, because the 
medical records, especially of those who die are generally incomplete and it is not possible to 
evaluate objectively clinical anomalies that occurred during the hours that preceded the arrest 
and which constituted a point of interest to this study.  
For statistical purposes when a patient had more than one cardiac arrest, only the first 
episode was considered. 
Definition of end of event 
The end of an event is defined as ROSC lasting >20 min or the termination of the 
resuscitation event with the patient declared dead due to being unresponsive to resuscitative 
efforts or a medical futility advance directive (DNR - Do Not Resuscitate).8 Sustained ROSC is 
defined as the single, continuous presence of palpable pulses for > 20 minutes.14  
Definition of monitored events 
Monitored events were those for which the patient had electrocardiographic or pulse 
oximetry monitoring in place at the time of arrest.  
Statistical analysis 
Descriptive statistics were computed for patient and event characteristics. Frequencies 
and percentages are presented for categorical data; medians with inter-quartile ranges are 
reported for non-normal, continuous data; t student test was performed to compare between 
pairs of continuous variables. Differences among the categories of monitored status were 
tested using χ2 tests for categorical data and Mann—Whitney U-test for non-normal, 
continuous data. Ninety-five percent confidence intervals were calculated for odds ratios (OR) 
and for relative risk (RR). Analyses were performed in GraphPad Prism 5 ®. Statistical 
significance was defined as p < 0.05.  
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Results 
A total of 149 results were retrieved from the codification centre search and the 
respective files were analyzed. Among these, 31 were excluded because the arrests had 
occurred outside the hospital or in patients younger than 18 years old, 1 was excluded because 
the diagnosis in the medical records was of peri-arrest, with no evidence of an actual arrest. 
Finally, 55 patients had been in the hospital for less than 24 hours prior to the arrest and were, 
therefore, excluded. In the end, 66 medical files were reviewed. There were only 3 MET´s 
charts available for the included patients.  
Hospital characteristics 
Hospital São João is a tertiary hospital in Porto, Portugal. The hospital has a total of 53 
intermediate/intensive care unit beds. In 2009, 42,990 patients were released from the various 
hospital departments and the mortality rate was 3.17%.  
A MET was created in 1999. The team consists of a doctor and a nurse, both with 
training in advanced life support (ALS) as well as experience in management of critical patients. 
The MET is activated around 480 times a year, with 35-40% of these calls being for cardiac 
arrest. 
Patient characteristics 
The mean age was 69 years (table 1). Thirty eight (57.6%) were male and 28 (42.4%) 
were female. Fifty five percent were admitted to the hospital due to medical reasons, 35% due 
to surgical reasons and 10% due to trauma.  
Regarding pre-existing morbidities, about 15% had history of myocardial infarction, 
32% of heart failure, 33% had renal insufficiency, 20% respiratory insufficiency and 38% had 
diabetes mellitus (DM). 
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Five patients had two cardiac arrests, all but one on the same day. Three of them died 
during the second event and the other two survived to discharge. Only two patients had a 
history of cardiac arrest in previous hospital admissions. 
Event characteristics 
 About 30% of patients had cardiac arrest in the Intensive Care Unit and 36% in the 
general inpatient area (table 1). Only 12% of patients had a shockable rhythm and it was not 
possible to ascertain the first rhythm in 24% of cases.  
The mean inpatient days between admission and cardiac arrest was 15.5 days and 
between cardiac arrest and discharge was 22 days. 
There were clinical abnormal observations in 83% of patients during the 24 hours prior 
to cardiac arrest, namely acute respiratory insufficiency or compromise in 42% and 
haemodynamic instability/hypotension in 49%.  
Outcomes  
It was possible to restore spontaneous circulation in 88% of patients (table 2). Twenty 
patients were discharged alive. Three of them died within one year after the event and 6 were 
lost in follow up. Therefore, one year survival after arrest of those discharged alive could be 
considered between 55% and 85%. 
All patients with shockable rhythms had ROSC, but only 25% survived until discharge. 
Only one patient with ventricular fibrillation (VF) did not have a record of having received 
defibrillation.  
The Charlson score did not differ significantly in patients with/without ROSC, although 
it was lower for patients without ROSC. The initial rhythm observed in cardiac arrest did not 
influence the ROSC after ALS or the proportion of patients who survived to hospital discharge 
(table 6). The rhythm did not influence the time of death and neither the crude OR nor the RR 
was statistically significant. 
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Monitored vs. unmonitored 
 In order to evaluate the differences between patients which were monitored at the 
time of event and those who were not, various parameters were compared between them 
(tables 3 and 4). Forty patients (61%) were monitored and 26 (39%) were unmonitored.   
 Most patients with a cardiac illness were monitored at the time of event (p=0.02), as 
were trauma patients. Pre-existing conditions did not differ between the two groups (p=0.25) 
and the Charlson score was not significantly different either. 
 Shockable rhythms occurred only in monitored patients, but asystole occurred in equal 
proportions (35% in both groups). 
There were no significant differences in ROSC (OR=2.9, 95% CI: 0.637-13.54), survival 
24hours past event (OR=1.12, 95% CI: 0.412-3.023) and at discharge (OR= 1.8, 95% CI: 0.586-
5.503) between the monitored and unmonitored groups. 
Death in hospital vs. alive at discharge 
 In order to identify possible predictive factors of poor prognosis after cardiac arrest, 
the patients who died in the hospital and those who survived until discharge were compared 
(table 5). 
 Mean age was not significantly different between the two groups. Cardiovascular risk 
factors and pre-existing conditions were not different either. The mean Charlson score was 
equal for the two groups. The monitored status was not related with better outcome. 
 The mean in-hospital days after cardiac arrest was significantly higher in survivors (45 
days) than in non-survivors (13 days) (p=0.01). 
Discussion  
Schein et al.9 considered that one of the central questions of resuscitation research so 
far should be to what degree do in-hospital cardiopulmonary arrests represent predictable 
events.  In this study, various possible predictive factors of cardiac arrest were analysed: 
previous morbidities, reason for admission and clinical anomalies preceding the event. 
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We also tried to compare the groups of monitored and unmonitored patients and of 
those who died in-hospital and those who survived to discharge, in order to, in the former 
case, uncover if monitoring could be a relevant factor for survival after arrest or if patients 
monitored and unmonitored that experience an arrest have different features; and in the 
latter, to make an attempt at describing predictors of survival and risk factors to poor 
outcome. 
Patient characteristics 
Approximately a third of the patients had a history of congestive heart failure or renal 
insufficiency or DM, three important comorbidities. In a study conducted on another 
Portuguese hospital, the prevalence of these comorbidities was somewhat different (40% 
cardiac disease, 16% chronic renal disease, 16% diabetes).15 Concerning diabetes, it is regarded 
as a common feature in patients suffering in-hospital cardiac arrest and is considered a strong 
predictor of mortality.16 
Event characteristics 
Most patients (> 80%) had clinical anomalies related to airway, breathing, circulation 
or neurologic dysfunction, which is the ABCD of approach to a cardiac arrest. 
 The ACADEMIA study17 also reported that 79.4% of cardiac arrests studied had 
evidence of abnormal physiology prior to the event, the most frequently reported 
abnormalities being low systolic blood pressure and a fall in Glasgow Coma Scale. 
Furthermore, a review of interventions aimed at anticipating and preventing in-hospital 
cardiac arrests concluded that critical physiological changes had been described in 51–86% of 
patients who had suffered a subsequent cardiopulmonary arrest in the general wards, often 
several hours before the arrest. The physiological changes described in the studies reviewed 
included respiratory insufficiency, change in mental status, hypotension, among others,2 which 
is consistent with the results of this study.  
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The most common initial rhythm was asystole and almost 2/3 of the patients had an 
initial non-shockable rhythm, which is in agreement with other studies.8,18 
Outcomes 
The survival to discharge in this study was 30.3%. A previous study conducted also in 
Hospital São João in 1992 revealed a survival rate of only 5%,19 however, the differences in the 
methodology do not permit making comparisons concerning a decrease in mortality after 
cardiac arrest in this hospital. Another study in a general nonteaching Portuguese hospital 
presented survival rates of 31% in a 2005-2006,20 which is similar to our study. 
In two studies from the USA based on the NRCPR (National Registry of 
Cardiopulmonary Resuscitation) the survival to discharge was around 17%8 and 15.9%.21 The 
difference between these figures and ours is probably mainly related to differences in 
methodology and sample size. 
Furthermore, ROSC occurred in about 88% of patients, whereas in other studies it was 
only 44%.1,8 This could translate an absence or lack of use of DNR, through the performance of 
resuscitation manoeuvres in patients that would otherwise not have an indication for such an 
aggressive treatment.  
 In relation to survival according to initial rhythm, our study reveals distinct results 
comparing to other studies, having a higher survival rate for non-shockable rhythms (21.7% for 
asystole and 42.1% for pulseless electrical activity (PEA) vs. 10% for asystole and PEA in the 
NRCPR study).8 It is not possible to draw any specific conclusions from this difference, given 
that almost 25% of the patients in our study did not have a record of the initial rhythm, which 
reinforces the need for better registries concerning in-hospital cardiac arrests. 
 One year survival was about 55-85%, which is comparable with the 80% survival at one 
year obtained in another study.22 
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Monitored vs. unmonitored 
 The illness category is relevant in the monitored vs. unmonitored status at the time of 
event, given that all patients in the “surgical cardiac” and 9 out of 11 in the “medical cardiac” 
category were monitored, which demonstrates that these are usually considered critical 
patients. Brady et al.23 also obtained significant differences in illness category between 
monitored and unmonitored patients. 
 Nevertheless, there were no statistically significant differences between the two 
groups when comparing for pre-existing conditions, cardiovascular risk factors or the Charlson 
score. This could just be a consequence of a small sample. In fact, Brady et al.23 found 
differences in pre-existing conditions between monitored and/or witnessed and 
unmonitored/unwitnessed patients for pre-existing conditions such as myocardial infarction, 
history of heart failure, DM, respiratory insufficiency, pneumonia, renal insufficiency, cancer 
and major trauma, among others. 
The outcomes were not different either. However, Brady et al.23 described that 
patients who are witnessed and/or monitored at the time of cardiac arrest demonstrate a 
significantly higher rate of survival to hospital discharge compared to those patients who are 
neither monitored nor witnessed. Again, the small sample in this study could explain why there 
were no differences in outcome between the groups. 
All patients that have an initial shockable rhythm were monitored, which could 
represent the earliest recognition of cardiac arrest and evaluation of rhythm. This preferable 
occurrence of shockable rhythms in monitored patients is in agreement with the study of 
Brady et al.,23 where pulseless ventricular tachycardia and VF were also seen with increased 
frequency in the monitored units. It should be noted that there was a lack of registration of 
initial rhythm in 25% of monitored patients. 
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Death in hospital vs. alive at discharge 
The average hospital length of stay after an index event was about 12 days for those 
who died in the hospital and about 45 days for survivors, which is considerably more than in 
the NRCPR study, which accounted an average hospital length of stay of 13.4 days for survivors 
and 1.5 days for those who died in the hospital.8 This difference could, at least in part, be 
explained by our exclusion of patients who had an index event <24hours after admission in the 
hospital. 
In this study, the registration of clinical anomalies before cardiac arrest was not 
significantly different between survivors and non-survivors. This might just be the result of a 
small sample, as, in another study, survival to hospital discharge was lower in those with 
abnormal vital signs (9%) compared to those with normal vital signs (20%) and those with no 
documentation of vital signs (14%).7 
Regarding the Charlson score, there were no statistically significant differences 
between the two groups. It was not possible to find other studies evaluating the Charlson 
score in cardiac arrest patients, however a study comparing pre-arrest morbidity and 
outcome24 found that there was no difference in survival associated with the presence or 
absence of morbidity before hospital admission, although there were differences between the 
morbidities. 
Moreover, in this study, it does not appear to be any differences in pre-existing 
conditions between the group of patients who died and those who survived to discharge. 
Nevertheless, a meta-analysis of pre-arrest predictors of failure to survive25 concluded that any 
malignancy, 'end-stage disease' and impaired renal function were co-morbid conditions 
significantly associated with non-survival. Non-cardiac diagnoses, pneumonia and trauma on 
admission were also associated with failure to survive to discharge, whereas cardiovascular 
diagnosis and co-morbidities were associated with a greater likelihood of survival. Larkin et 
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al.21 also described a higher risk of death at the event and at discharge in patients with pre-
existing hypotension, respiratory insufficiency, acute stroke, pneumonia and trauma.  
The patients who died received defibrillation more frequently than those who survived 
(p= 0.02). This could just translate better registries for the patients who died or those patients 
had a worst clinical situation from the beginning.  
Limitations 
This study suffers from the typical problems associated with retrospective studies: the 
potential inaccuracy of data and its absence. The sample size is also small and may not be 
representative. Moreover, the MET´s compliance in obtaining more rigorous records in 
accordance with the Utstein model needs to be improved.  
Conclusions 
 This study, due to its small sample size, did not retrieve many results that can be 
transposed. However, it is possible to conclude that survival to discharge after in-hospital 
cardiac arrest in Hospital S. João in 2009 was 30.3% and one year survival was between 17% 
and 26%. It was not possible to find significant predictive factors for cardiac arrest. There were 
no significant differences between monitored and unmonitored patients regarding pre-existing 
conditions, characteristics of event and outcome. We could not find distinctive characteristics 
between patients who died in-hospital and those who survived, except for a longer in-hospital 
stay for survivors and more frequent defibrillation in non-survivors. 
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Tables 
Table 1. Patient and index event characteristics.  
N 66 
Age (years)  
Mean± S.D. 69.3 ± 15.0 
Median (25th, 75th) 73 (62.5, 80.0) 
Range 25 – 92 
Sex N (%)  
Male 38 (57.6%) 
Female 28 (42.4%) 
Subject type – Inpatient N (%)  
General Surgery 6 (9.1%) 
Cardiothoracic Surgery 5 (7.6%) 
Vascular Surgery 2 (3.0%) 
Orthopaedics – Trauma 4 (6.1%) 
Urology 3 (4.6%) 
Otorhinolaryngology 1 (1.5%) 
Burn Unit 1 (1.5%) 
Emergency Department 2 (3.0%) 
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Internal Medicine 11 (16.7%) 
Intensive Care Unit 18 (27.3%) 
Infectious Diseases 1 (1.5%) 
Stroke Unit 1 (1.5%) 
Cardiology – Coronary Unit 7 (10.6%) 
Nephrology – Transplant Unit 3 (4.7%) 
Haematology 1 (1.5%) 
Illness category N (%)  
Medical, cardiac 11 (16.7%) 
Medical, noncardiac 25 (38.0%) 
Surgical, noncardiac 19 (28.9%) 
Surgical, cardiac 4 (6.1%) 
Trauma 7 (10.6%) 
Pre-existing conditions * N (%)  
Acute myocardial infarction 8 (12.1%)  
History of myocardial infarction 10 (15.2%) 
Arrhythmia 9 (13.6%) 
History of congestive heart failure  21 (31.8%) 
Acute neurologic  event (nonstroke) 6 (9.1%) 
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Acute stroke 3 (4.7%) 
Respiratory insufficiency 13 (19.7%) 
Pneumonia on admission  4 (6.1%) 
Sepsis on admission 5 (7.7%) 
Other infection on admission 8 (12.1%) 
Hepatic insufficiency 3 (4.7%) 
Renal insufficiency 22 (33.3%) 
Cancer (last 5 years) 12 (18.2%) 
Diabetes mellitus 25 (37.9%) 
Major trauma 6 (9.1%) 
Toxicological problem 0 (0.0%) 
None reported 4 (6.1%) 
Event location N (%)  
ICU  20 (30.3%) 
Inpatient  24 (36.4%) 
Emergency room 7 (10.6%) 
Diagnostic area  1 (1.5%) 
Operating room  1 (1.5%) 
Intermediate- Care Unit 5 (7.7%) 
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Other 3 (4.7%) 
Discovery status at time of event N (%)  
Monitored  40 (60.6%) 
Unmonitored 26 (39.4%) 
Cardiac arrest initial rhythm N (%)  
VF/pulseless VT  8 (12.14%) 
PEA  19 (28.8%) 
Asystole  23 (35.0%) 
Unknown by documentation  16 (24.2%) 
Inpatient days before cardiac arrest  
Mean± S.D. 15.5 ± 16.2 
Median (25th, 75th) 8.5 (4.0, 24.3) 
Range  1.0 – 75.0 
Inpatient days after cardiac arrest  
Mean± S.D. 22.3  ± 48.4  
Median (25th, 75th) 7.5 (0.5, 19.3) 
Range  0 – 342 
ROSC N (%)  
Restored 58 (87.8%) 
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Non sustained 8 (12.2%) 
Advanced life support time procedures (minutes)  
Mean± S.D. 8.6 ± 10.4 
Median  (25th, 75th) 6.0  (2.0 – 10.0) 
Range  2.0 – 60.0 
Reason to suspend ALS N (%)  
Re-established circulation 50 (75.8%) 
DNR/dead 4 (6.1%) 
Not possible 1 (1.2%) 
Not known (not registered) 11 (16.7%) 
Clinical abnormal observations 24hours prior to cardiac arrest N (%)  55 (83.3%) 
Airway obstruction  4 (6.1%) 
Acute respiratory insufficiency or compromise  28 (42.4%) 
Hypotension  21 (31.8%) 
Haemodynamic instability 11 (16.7%) 
Arrhythmia  14 (21.2%) 
CNS depression 10 (15.2%) 
Acute myocardial infarction or ischemia  1 (1.5%) 
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Destination after cardiac arrest N (%)  
ICU 26 (39.4%) 
Emergency room 28 (42.4%) 
Ward 2 (3.0%) 
Dead 8 (12.1%) 
Unknown/not registered 2 (3.0%) 
Interval time between cardiac arrest and death (days)**  
Mean± S.D. 19.5 ± 36.6 
Median  (25th, 75th) 6.0 (1.0, 16.5) 
Range  0.0 – 160.0 
ALS: Advanced Life Support; CNS: central nervous system; DNR: do not resuscitate; ICU: Intensive Care 
Unit; PEA: pulseless electric activity; ROSC: return of spontaneous circulation; VT: ventricular 
tachycardia; VF: ventricular fibrillation.  
* Several patients had more than one pre-existing condition. 
** It includes follow up until 12 months after cardiac arrest. 
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Table 2. Overall survival rate for index events  and Charlson score for patients with/without ROSC 
Cardiac arrest 
initial rhythm 
N (%) 
ROSC after ALS 
N (%) 
p 
Survival to 
hospital 
discharge N (%) 
P 
VF/pulseless VT  8 (12.1%) 8 (100.0%)  2 (25.0%)  
PEA  19 (28.8%) 17 (89.5%)  8 (42.1%)  
Asystole  23 (35.0%) 20 (87.0%)  5 (21.7%)  
Unknown by documentation 16 (24.2%) 13 (81.3%)  5 (31.3%)  
   0.97 (1)  0.77 (2) 
Overall  66 58 (87.9%)  20 (30.3%)  
Charlson score (age adjusted) 
 
ROSC 
N= 58 (87.9%) 
Without ROSC 
N=8 (12.1%) 
p value 
Mean ± S.D. 5.7± 2.9 4.0 ± 3.3 0.18 
Median (25th, 75th) 6.0 (4.0, 7.0) 3.0 (1.3, 7.0) 
 
Range 0.0 – 17.0 0.0 – 9.0 
ALS: advanced life support; PEA: pulseless electric activity; ROSC: return of spontaneous circulation; VF: 
ventricular fibrillation; VT: ventricular tachycardia. 
(1) p=0.97 – cardiac arrest initial rhythms (asystole; PEA; VF/VT) and proportion of patients with 
ROSC. 
(2) p=0.77 – initial rhythms (asystole; PEA; VF/VT) and proportion of patients surviving until 
hospital discharge. 
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Table 3. Monitored and Unmonitored patients. Characteristics.  
Demographic characteristics, illness category, pre-existing conditions, cardiovascular risk factors, 
Charlson score (comorbidity index), cardiac arrest initial rhythm, time of arrest, drug therapy at the time 
of arrest, duration of event and in-hospital days after cardiac arrest.  
 
Monitored  
N = 40 (60.6%) 
Unmonitored  
N = 26 (39.4%) 
p value 
Age  (years)    
Mean± S.D. 68.3 ± 15.5 70.9 ± 14.4 0.52 
Median  (25th, 75th) 73.0 (64.0 – 80.0) 72.0 (60.0 – 80.3)  
Range 25 – 88 26 – 92  
Male sex N (%) 24 (60.0%) 14 (54.0%)  
Age, mean ±  SD (years) 65.9  ± 16.8 75.5 ± 11.5 0.06 
Female sex N (%) 16 (40.0%) 12 (46.2%)  
Age, mean ± SD (years) 72.1 ± 13.3 65.3 ± 15.9 0.23 
Male vs. Female   0.62 
Illness category N (%)   0.04 
Medical, cardiac 9 (22.5%) 2 (7.8%)  
Medical, non-cardiac 11 (27.5%) 14 (54.0%)  
Surgical, cardiac 4 (10.0%) 0 (0.0%)  
Surgical, non-cardiac 10 (25.0%) 9 (34.6%)  
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Trauma 6 (15.0%) 1 (3.9%)  
Cardiac / non-cardiac 13/27 2/24 0.02 
Pre-existing conditions N (%)   0.25 
Acute myocardial infarction 5 (12.5%) 3 (11.5%)  
History of myocardial infarction 7 (17.5%) 3 (11.5%)  
Arrhythmia 7 (17.5%) 2 (7.8%)  
History of congestive heart failure 11 (27.5%) 10 (38.6%)  
Acute neurologic event (nonstroke) 6 (15.0%) 0 (0.0%)  
Acute stroke 1 (2.5%) 2 (7.8%)  
Respiratory insufficiency 9 (22.5%) 4 (15.4%)  
Pneumonia on admission 1 (2.5%) 3 (11.5%)  
Sepsis on admission 2 (5.0%) 3 (11.5%)  
Other infection on admission 4 (10.0%) 3 (11.5%)  
Hepatic insufficiency 2 (5.0%) 1 (3.9%)  
Renal insufficiency 15 (37.5%) 7 (26.9%)  
Cancer (last 5 years) 7 (17.5%) 5 (19.2%)  
Major trauma 6 (15.0%) 0 (0.0%)  
None reported 1 (2.5%) 3 (11.5%)  
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Cardiovascular risk factors N (%)   0.75 
Diabetes mellitus 15 (37.5%) 10 (38.5%)  
Tobacco 6 (15.0%) 8 (30.8%)  
Obesity 2 (5.0%) 3 (11.5%)  
Dislipidemia 9 (22.5%) 5 (19.2%)  
High blood pressure 16 (40.0%) 17 (65.4%)  
Without risk factors 9 (22.5%) 6 (23.1%)  
Charlson score (age adjusted)    
Mean ± S.D. 5.3 ± 3.3 5.8 ± 2.5 0.28 (1) 
Median (25th, 75th) 5.0 (2.0, 7.0) 6.0 (4.0, 7.0)  
Range 0.0 – 17.0 0.0 – 11.0  
Cardiac arrest initial rhythm N (%)    
Ventricular fibrillation 6 (15.0%) 0 (0.0%)  
Pulseless ventricular tachycardia 2 (5.0%) 0 (0.0%)  
Pulseless electrical activity  8 (20.0%) 11 (34.6%)  
Asystole 14 (35.0%) 9 (34.6%)  
Unknown 10 (25.0%) 6 (23.1%)  
Time of event (*)   0.64 
8:00 AM to 5:59 PM 11 (27.5%) 11 (34.6%)  
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6:00 PM to 10:59 PM 6 (15.0%) 5 (19.2%)  
11:00 PM to 7:59 AM 10 (25.0%) 4 (15.4%)  
Weekend 10 (25.0%) 8 (30.8%)  
Drugs administered during ALS 
 N (%) 
  0.37 (2) 
Adrenaline (Epinephrine) 14 (35.0%) 13 (50.0%)  
Dobutamine 1 (2.5%) 0 (0.0%)  
Dopamine 0 (0.0%) 0 (0.0%)  
Noradrenaline (Norepinephrine) 3 (7.5%) 1 (3.9%)  
Amiodarone 8 (20.0%) 0 (0.0%)  
Lidocaine 2 (5.0%) 0 (0.0%)  
Atropine 9 (22.5%) 14 (53.9%)  
Calcium chloride/calcium gluconate 4 (10.0%) 3 (11.5%)  
Fluid bolus for volume expansion 0 (0.0%) 4 (15.4%)  
Magnesium sulfate 2 (5.0%) 0 (0.0%)  
Sodium bicarbonate 3 (7.5%) 8 (30.8%)  
None/not registered 25 (62.5%) 9 (34.6%)  
Event duration (minutes)    
Mean ± S.D. 7.4 ± 7.0 10.4 ± 13.9 0.24 
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Median  (25th, 75th) 5.0 (2.0 – 10.0) 6.0 (4.0 – 10.0)  
Range 2.0 – 30.0 2.0 – 60.0  
In-hospital days after cardiac arrest 
 (mean ±S.D.) 
25.3 ± 57.7 17.7 ± 29.5 0.54 
ALS: Advanced Life Support  
* Periods of time are according to usual nurse shifts. 
1) Mann-Whitney U test 
2) Considering only the use of adrenaline and atropine 
Table 4. Monitored and Non-Monitored patients. Outcomes.  
 Total N=66 
Monitored 
N= 40 (60.6%) 
Unmonitored  
N = 26 (39.4%) 
p OR (95% CI) 
ROSC >20 min 
N (%) 
58 (87.9%) 37 (56.1%) 21 (31.8%) 0.15 
2.9 
(0.637- 13.54) 
Survived 24 h past event  
N (%) 
29 (43.9%) 18 (27.3%) 11 (16.7%) 0.83 
1.12  
(0.412 - 3.023) 
Survived to discharge 
 N (%) 
20 (30.3%) 14 (21.2%) 6 (9.1%) 0.70 
1.8  
(0.586 - 5.503) 
Death in-hospital N (%) 46 (69.7%) 26 (65.0%) 20 (76.9%) 0.30  
Death during CPR 
manoeuvres N (%) 
8 (12.1%) 6 (15.0%) 5 (19.2%) 0.65 
 
Death in-hospital after CPR 
manoeuvres N (%) 
38 (57.6%) 23 (57.5%) 15 (57.7%) 0.18 
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Post-discharge cumulative 
N (%) 
3 (4.5%) 2 (5.0%) 1 (3.9%)  
 
0-3 months 2 (3.0%) 1 (2.5%) 1 (3.9%)   
0-6 months 3 (4.5%) 2 (5.0%) 1 (3.9%)   
0-12 months 3 (4.5%) 2 (5.0%) 1 (3.9%)   
Cause of death N (%)      
Cardiac 8 (12.1%) 6 (15.0%) 2 (7.7%)   
Other medical cause 36 (54.6%) 19 (47.5%) 17 (65.4%)   
Trauma 3 (4.6%) 3 (7.5%) 0 (0.0%)   
Surgical cause 2 (3.0%) 0 (0.0%) 2 (7.7%)   
Other 1 (1.2%) 1 (2.5%) 0 (0.0%)   
Cardiac/non-cardiac cause  6/23 2/19 0.29  
Alive at discharge N (%) 20 (30.3%) 14 (35.0%) 6 (23.1%)   
Alive after 12 months N (%) 11 (16.7%) 7 (17.5%) 4 (15.4%)   
Lost in follow up N (%) 6 (9.1%) 5 (12.5%) 1 (5.0%)   
OR: odds ratio; ROSC: return of spontaneous circulation. 
 
 
 
 
 
 31 
 
Table 5. Death in-hospital and patients alive at discharge. 
 Demographic characteristics, illness category, pre-existing conditions, cardiovascular risk factors, 
Charlson score (comorbidity index), previous heart disease, monitored and unmonitored patients,  
infectious diseases, in-hospital days after cardiac arrest, cardiac arrest initial rhythm, defibrillation, time 
of event and duration, clinical abnormal observations prior to cardiac arrest. 
 
Death in-hospital 
N = 46 (69.7%) 
Alive at discharge 
N =20 (30.3%) 
p value 
Age  (years)    
Mean± S.D. 68.6 ± 16.0 70.8 ± 12.9 0.59 
Median  (25th, 75th) 73 (59.8, 80.0) 82 (64.8, 80.8)  
Range 25 – 92 29 – 86  
Sex   0.79 
Male 26 (56.5%) 12 (26.1%)  
Female 20 (43.5%) 8 (17.4%)  
Illness category N (%)    
Medical, cardiac 7 (15.2%) 4 (8.7%)  
Medical, non-cardiac 21 (45.8%) 4 (8.7%)  
Surgical, cardiac 12 (26.1%) 7 (15.2%)  
Surgical, non-cardiac 2 (4.4%) 2 (4.4%)  
Trauma 4 (8.7%) 3 (6.5%)  
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Cardiac / non-cardiac 19/27 11/9 0.30 
Pre-existing conditions N (%)   0.70 
Acute myocardial infarction 5 (11.0%) 3 (15.0%)  
History of myocardial infarction 6 (13.0%) 4 (20.0%)  
Arrhythmia 4 (8.7%) 5 (25.0%)  
History of congestive heart failure 15 (32.6%) 6 (3.0%)  
Acute stroke 2 (4.4%) 1 (5.0%)  
Respiratory insufficiency 7 (15.2%) 6 (3.0%)  
Pneumonia on admission 2 (4.4%) 1 (5.0%)  
Sepsis on admission 5 (11.0%) 0 (0.0%)  
Other infection on admission 5 (11.0%) 2 (10.0%)  
Hepatic insufficiency 3 (6.5%) 0 (0.0%)  
Renal insufficiency 17 (37.1%) 5 (25.0%)  
Cancer (last 5 years) 9 (19.6%) 3 (15.0%)  
Major trauma 3 (6.5%) 3 (15.0%)  
None reported 2 (4.4%) 2 (10.0%)  
Cardiovascular risk factors N (%)   0.77 
Diabetes Mellitus 16 (34.8%) 9 (45.0%)  
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Tobacco 7 (15.2%) 7 (35.0%)  
Obesity 3 (6.52%) 2 (10.0%)  
Dislipidemia 8 (17.4%) 6 (3.0%)  
High blood pressure 23 (50.0%) 10 (5%)  
Without risk factors 11 (23.9%) 4 (20.0%)  
With/ Without cardiovascular risk factors 35/11 16/4 0.73 
Charlson score (age adjusted)    
Mean ± S.D. 5.5 ± 3.2 5.5 ± 2.6 0.91 (1) 
Median (25th, 75th) 5.0 (3.0, 7.0) 6.0 (4.3, 7.0)  
Range 0.0 – 17.0 0.0 – 11.0  
Previous heart disease N (%) 16 (34.8%) 12 (60.0%) 0.06 
Monitored N (%) 26 (56.5%) 14 (70.0%)  
Unmonitored N (%) 20 (43.6%) 6 (3.0%)  
Monitored/unmonitored   0.30 
Infections (admission + in-hospital) N (%)   0.50 
Pneumonia 19 (41.3%) 9 (45.0%)  
Sepsis/septic shock 20 (43.6%) 5 (25.0%)  
Bacteraemia 8 (17.4%) 6 (3.0%)  
Other 15 (32.6%) 6 (3.0%)  
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In-hospital days after cardiac arrest    
Mean ±S.D. 12.7 ± 26.3 44.6 ± 75.2 0.01 
Median (25th, 75th) 2.8 (0.1, 14.1) 17.5 (8.0, 52.0)  
Range 0.0 – 121.0 5.0 – 342.0  
Cardiac arrest initial rhythm N (%)   0.54 
VF/ pulseless VT 6 (13.1%) 2 (10.0%)  
Pulseless electrical activity  11 (23.9%) 8 (40.0%)  
Asystole 18 (39.1%) 5 (25.0%)  
Unknown 11 (23.9%) 5 (25.0%)  
Defibrillation N (%)    
Patients who received defibrillation  15 (37.5%) 1 (3.9%) 0.02 
Time of event (*) N (%)    
8:00 AM to 5:59 PM 15 (32.6%) 7 (35.0%)  
6:00 PM to 10:59 PM 9 (19.6%) 2 (10.0%)  
11:00 PM to 7:59 AM 11 (23.9%) 3 (15.0%)  
Weekend 15 (32.6%) 3 (15.0%)  
Event duration (minutes)    
Mean ± S.D. 7.5 ± 7.2 10.7 ± 14.2 0.23 
Median  (25th, 75th) 5.0 (2.0, 10.5) 8.0 (4.0, 10.0)  
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Range 2.0 – 35.0 2.0 – 60.0  
Clinical abnormal observations 
24hours prior to cardiac arrest N (%) 
40 (87.0%) 15 (75.0%) 0.57 
Airway obstruction  2 (4.3%) 2 (10.0%)  
Acute respiratory insufficiency or compromise  18 (39.1%) 10 (50.0%)  
Hypotension  15 (32.6%) 6 (30.0%)  
Haemodynamic instability 9 (19.6%) 2 (10.0%)  
Arrhythmia  10 (21.7%) 4 (20.0%)  
CNS depression 9 (19.6%) 1 (5.0%)  
CNS: central nervous system; VF: ventricular fibrillation; VT: ventricular tachycardia. 
* Periods of time are according to usual nurse shifts. 
(1) Mann-Whitney U test 
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Table 6. Pre-resuscitation facts and association with outcome (N=66)  
Event specific data 
Prevalence 
% (N) 
% (N)  
Died at 
event 
% (N) Died 
at 
discharge 
Crude OR of 
discharge 
mortality; 95% CI 
RR of discharge 
mortality ; 
95% CI * 
Monitored 60.6% (40) 15.0% (6) 65.0% (26) 0.56 (0.18-1.71) 0.85 (0.62-1.15) 
First documented 
pulseless rhythm 
     
Asystole  34.9% (23) 13.0% (3) 78.3% (18) 1.93 (0.60-6.23) 1.20 (0.88-1.64) 
PEA  28.8% (19) 5.3% (1) 57.9% (11) 0.47 (0.15-1.45) 0.78 (0.51-1.18) 
VF or pulseless VT 12.1% (8) 0.0 % (0) 75.0% (6) 1.35 (0.25-7.35) 1.09 (0.70-1.68) 
Missing/unknown 24.2% (16) 25.0% (4) 68.8% (11)   
OR: odds ratio; PEA: pulseless electric activity; RR: relative risk; VF: ventricular fibrillation; VT: ventricular 
tachycardia;  
*All values of p>0.05 
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